Profil:
Neuca SANeuca pharma posts Q3 EBITDA of PLN 109.2 mln
Listed pharmaceutical company Neuca posted third quarter 2025 EBITDA of PLN 109.2 million (EUR 25.7 mln) and attributable net profit of PLN 60.2 million (EUR 14.2 mln), the company said in its finanacial report.
PLN mln
| 3Q2025 | results | consensus | difference | y/y | q/q | YTD 2025 | y/y |
| revenues | 3489.0 | 3410.0 | 2.3% | 9.5% | 6.8% | 10123.0 | 7.8% |
| EBITDA | 109.2 | 100.1 | 9.1% | 0.8% | 46% | 294.4 | -6.8% |
| EBIT | 78.5 | 68.0 | 15% | 0,1% | 82% | 201.0 | -11% |
| attrib. net profit | 60.2 | 41.4 | 45% | 44% | 203% | 128.4 | -0.4% |
| EBITDA margin | 3.1% | 2.9% | 0.19 | -0.27 | 0.85 | 2.91% | -0.45 |
| EBIT margin | 2.2% | 2.0% | 0.25 | -0.21 | 0.93 | 1.99% | -0.43 |
| net margin | 1.7% | 1.2% | 0.51 | 0.41 | 1.12 | 1.27% | -0.10 |
pr/ nl/